Effect of gemfibrozil on serum lipid levels.
A short term investigation of the effect of Gemfibrozil in 1200 mg daily doses has been carried out in a group of 20 Swedish males, 9 Lp[a+] and 11 Lp[a-]. The effect of 8 weeks of treatment upon serum lipids resembled those found in previous trials, with a significant decrease in serum total cholesterol. In this series, even VLDL cholesterol and apoB levels decreased significantly. With the apparent exception of HDL cholesterol, there was no suggestion that Lp[a+] individuals responded less well to treatment than did Lp[a-] individuals.
D002784:Cholesterol / Q000097:blood; D002986:Clinical Trials as Topic; D015248:Gemfibrozil; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000097:blood / Q000188:drug therapy; D006953:Hyperlipoproteinemia Type IV / Q000097:blood / Q000188:drug therapy; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008055:Lipids / Q000097:blood*; D008074:Lipoproteins / Q000097:blood; D008297:Male; D008875:Middle Aged; D010421:Pentanoic Acids / Q000627:therapeutic use*; D014280:Triglycerides / Q000097:blood; D014631:Valerates / Q000627:therapeutic use*; D014992:Xylenes / Q000627:therapeutic use
D000960:Hypolipidemic Agents; D008055:Lipids; D008074:Lipoproteins; D010421:Pentanoic Acids; D014280:Triglycerides; D014631:Valerates; D014992:Xylenes; D002784:Cholesterol; D015248:Gemfibrozil